Screener
Dianthus Therapeutics DNTH Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Accrued expenses | 31,125 | 19,452 |
| Current portion of deferred revenue | 1,485 | 1,188 |
| Current portion of operating lease liabilities | 399 | 367 |
| Total current liabilities | 38,283 | 30,732 |
| Deferred revenue | 6,322 | 5,770 |
| Long-term operating lease liabilities | 965 | 1,019 |
| Total liabilities | 45,570 | 37,521 |
| Commitments and contingencies (Note 14) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's total current liabilities?
- Dianthus Therapeutics (DNTH) reported total current liabilities of $38.28M in Q1 2026.
- How has Dianthus Therapeutics's total current liabilities changed year-over-year?
- Dianthus Therapeutics's total current liabilities increased by 125.8% year-over-year, from $16.95M to $38.28M.
- What is the long-term trend for Dianthus Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Dianthus Therapeutics's total current liabilities has grown at a 21.9% compound annual growth rate (CAGR), from $11.43M to $30.73M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Dianthus Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude